Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Venetoclax, rituximab, and ibrutinib with treatment adapted to undetectable MRD in treatment-naive CLL

Phase 2 trial in which treatment after cycle 12 depends on undetectable minimal residual disease in blood and bone marrow. The registry primary outcome is undetectable MRD by flow cytometry in the bone marrow. ClinicalTrials.gov lists the study as recruiting.

Paolo Ghia